## Answer
(model generated chain of thought explanation)

To solve this question, let's break it down step by step:

1. **Patient's symptoms and medical history**: The patient is a 71-year-old woman with hypertension and congestive heart failure presenting with palpitations and shortness of breath. These symptoms are concerning for cardiac arrhythmias.

2. **ECG findings**: The narrow-complex tachycardia without P waves indicates atrial fibrillation (AF), which is an irregularly irregular rhythm often associated with heart failure due to its pro-arrhythmic effects on the ventricles.

3. **Prophylactic medication and idarucizumab**: The patient is prescribed a prophylactic medication that can be reversed with idarucizumab, a direct thrombin inhibitor. This suggests that the medication targets a specific aspect of coagulation to prevent further clotting in the setting of AF.

4. **Mechanism of action of idarucizumab**: Idarucizumab is an antidote for warfarin-induced anticoagulation, which can be used to reverse the effects of direct thrombin inhibitors like rivaroxaban or apixaban. Direct thrombin inhibitors work by irreversibly inhibiting thrombin (factor IIa), a key enzyme in the coagulation cascade.

5. **Expected beneficial effect**: Given that idarucizumab is used to reverse the effects of a direct thrombin inhibitor, its expected beneficial effect would be related to the inhibition of thrombin activity.

Considering these points:

- A: Inhibition of thrombocyte phosphodiesterase III is not directly relevant to the mechanism of action of idarucizumab.
- B: Irreversible inhibition of GPIIb/IIIa complex is more closely associated with heparin, another type of anticoagulant that works through a different mechanism.
- C: Direct inhibition of factor Xa is characteristic of direct thrombin inhibitors like rivaroxaban and apixaban but not idarucizumab.
- D: Direct inhibition of thrombin is the correct answer as it aligns with the mechanism of action of idarucizumab.

Therefore, the expected beneficial effect of the prescribed drug (idarucizumab) in this scenario is most likely due to its direct inhibition of thrombin.